Search

• GSK to purchase Shenzhen Neptunus stake in previously formed joint venture for influenza vaccines in China

  Media

  GSK entered into agreement to acquire the remaining 51% equity interest of Neptunus in JV company for a total cash consideration of $39m

  https://www.gsk.com/en-gb/media/press-releases/gsk-to-purchase-shenzhen-neptunus-stake-in-previously-formed-joint-venture-for-influenza-vaccines-in-china/

  First published: 14 June 2011

• Sanofi and GSK selected for Operation Warp Speed to supply United States Government with 100 million doses of COVID-19 vaccine

  Media

  Promising COVID-19 vaccine candidate, developed by Sanofi in partnership with GSK, selected by U.S. government’s Operation Warp Speed.

  https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-selected-for-operation-warp-speed-to-supply-united-states-government-with-100-million-doses-of-covid-19-vaccine/

  First published: 31 July 2020

• Sanofi and GSK initiate global Phase 3 clinical efficacy study of COVID-19 vaccine candidate

  Media

  Pending positive Phase 3 outcomes and regulatory reviews, the vaccine could be approved in Q4 2021

  https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-initiate-global-phase-3-clinical-efficacy-study-of-covid-19-vaccine-candidate/

  First published: 27 May 2021

• Clover and GSK announce research collaboration to evaluate coronavirus (COVID-19) vaccine candidate with pandemic adjuvant system

  Media

  Clover and GSK Announce Research Collaboration to Evaluate Coronavirus (COVID-19) Vaccine Candidate with Pandemic Adjuvant System

  https://www.gsk.com/en-gb/media/press-releases/clover-and-gsk-announce-research-collaboration-to-evaluate-coronavirus-covid-19-vaccine-candidate-with-pandemic-adjuvant-system/

  First published: 24 February 2020

• Sanofi and GSK to supply European Union with up to 300 million doses of COVID-19 vaccine

  Media

  The agreement relates to vaccine candidate using Sanofi’s recombinant protein-based technology combined with GSK’s pandemic adjuvant system.

  https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-to-supply-european-union-with-up-to-300-million-doses-of-covid-19-vaccine/

  First published: 31 July 2020

• Sanofi and GSK in advanced discussions with European Union to supply up to 300 million doses of COVID-19 vaccine

  Media

  Discussions relate to vaccine candidate using Sanofi’s recombinant protein-based technology combined with GSK’s pandemic adjuvant system

  https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-in-advanced-discussions-with-european-union-to-supply-up-to-300-million-doses-of-covid-19-vaccine/

  First published: 31 July 2020

• Sanofi and GSK agree with the UK government to supply up to 60 million doses of COVID-19 vaccine

  Media

  Agreement relates to vaccine candidate using Sanofi’s recombinant protein-based technology combined with GSK’s pandemic adjuvant system.

  https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-agree-with-the-uk-government-to-supply-up-to-60-million-doses-of-covid-19-vaccine/

  First published: 29 July 2020

• Sanofi and GSK COVID-19 vaccine candidate demonstrates strong immune responses across all adult age groups in Phase 2 trial

  Media

  Adjuvanted recombinant COVID-19 vaccine candidate triggered strong neutralizing antibody responses in all adult age groups.

  https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-covid-19-vaccine-candidate-demonstrates-strong-immune-responses-across-all-adult-age-groups-in-phase-2-trial/

  First published: 17 May 2021

• Sanofi and GSK to seek regulatory authorization for COVID-19 vaccine

  Media

  Sanofi and GSK today announce that they intend to submit data from both their booster and Phase 3 efficacy trials

  https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-to-seek-regulatory-authorization-for-covid-19-vaccine/

  First published: 23 February 2022

• GSK’s RSV vaccine, Arexvy, accepted for regulatory review by the European Medicines Agency for the prevention of RSV disease in adults aged 50-59 at increased risk

  Media

  Application supported by positive results of a Phase III study showing immune response and acceptable tolerability profile.

  https://www.gsk.com/en-gb/media/press-releases/arexvy-accepted-for-regulatory-review-by-ema-for-prevention-of-rsv-in-adults-50-59/

  First published: 29 January 2024